Trial Profile
Comparative trial about efficacy, safety, pharmacokinetics similarity of multiple dosing on Chinese patients of advanced non-squamous and non-small cell lung cancer between recombinant anti-VEGF humanized monoclonal antibody injection combined carboplatin/paclitaxel chemotherapy and Bevacizumab combined carboplatin/paclitaxel chemotherapy : a mul
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jun 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Monoclonal antibodies; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Oct 2017 New trial record